Related Experiment Video
Updated: Jul 5, 2025

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Pulmonary Hypertension in Underrepresented Minorities: A Narrative Review
Johanna Contreras1, Jeremy Nussbaum1, Peter Cangialosi1
1Division of Heart Failure and Cardiac Transplantation, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Racial and ethnic minorities face higher rates of pulmonary hypertension (PH) and related conditions. Addressing social determinants of health and increasing research diversity are crucial for health equity.
Area of Science:
- Medical research
- Public health
- Cardiovascular and pulmonary medicine
Background:
- Minoritized racial and ethnic groups experience a disproportionate burden of pulmonary hypertension (PH) incidence and morbidity.
- Associated cardiovascular, pulmonary, and systemic conditions exacerbate health disparities in these populations.
- Social determinants of health, including healthcare access, systemic biases, socioeconomic status, and environmental factors, significantly contribute to these inequities.
Purpose of the Study:
- To highlight the significant health disparities in pulmonary hypertension (PH) affecting minority populations.
- To underscore the underrepresentation of minority patients in PH research.
- To advocate for targeted strategies to mitigate these disparities and promote health equity.
Main Methods:
- Literature review and analysis of existing data on PH prevalence and outcomes in diverse populations.
- Examination of the impact of social determinants of health on PH disparities.
- Assessment of minority participation in clinical trials and research studies related to PH.
Main Results:
- Data indicates a higher incidence and morbidity of PH among minoritized racial and ethnic groups.
- Social determinants of health are identified as primary drivers of these disparities.
- Minority patient representation in PH research remains significantly low, hindering the development of targeted interventions.
Conclusions:
- Urgent action is needed to address the disproportionate impact of PH on minority populations.
- Initiatives to enhance research participation among minority groups are essential for advancing PH knowledge and treatment.
- Combating inequities in healthcare access and improving the management of PH-associated conditions are critical steps toward achieving health equity.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

